Reto S Kohler1, Henriette Kettelhack1, Alexandra M Knipprath-Mészaros2, André Fedier1, Andreas Schoetzau1, Francis Jacob3, Viola Heinzelmann-Schwarz4. 1. Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel, University of Basel, Switzerland. 2. Hospital for Women, Department of Gynecology and Gynecological Oncology, University Hospital Basel, University of Basel, Switzerland. 3. Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel, University of Basel, Switzerland; Glyco-Oncology, Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel, University of Basel, Switzerland. Electronic address: francis.jacob@unibas.ch. 4. Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel, University of Basel, Switzerland; Hospital for Women, Department of Gynecology and Gynecological Oncology, University Hospital Basel, University of Basel, Switzerland. Electronic address: viola.heinzelmann@usb.ch.
Abstract
OBJECTIVE: Maternal embryonic leucine-zipper kinase (MELK) shows oncogenic properties in basal-like breast cancer, a cancer subtype sharing common molecular features with high-grade serous ovarian cancer. We examined the potential of MELK as a molecular and pharmacological target for treatment of epithelial ovarian cancer (EOC). METHODS/MATERIALS: Bioinformatic analysis was performed on nine OC transcriptomic data sets totaling 1241 patients. Effects of MELK depletion by shRNA or inhibition by OTSSP167 in cell lines were assessed by colony formation and MTT (proliferation) assays, Western blotting (apoptosis), and flow cytometry (cell cycle analysis). RESULTS: Elevated MELK expression was correlated with histological grading (n=6 data sets, p<0.05) and progression-free survival (HR 5.73, p<0.01) in OC patients and elevated MELK expression in other cancers with disease-free survival (n=3495, HR 1.071, p<0.001). Inhibition or depletion of MELK reduced cell proliferation and anchorage-dependent and -independent growth in various OC cell lines through a G2/M cell cycle arrest, eventually resulting in apoptosis. OTSSP167 retained its cytotoxicity in Cisplatin- and Paclitaxel-resistant IGROV1 and TYK-nu OC cells and sensitized OVCAR8 cells to Carboplatin but not Paclitaxel. CONCLUSION: MELK inhibition by OTSSP167 may thus present a strategy to treat patients with aggressive, progressive, and recurrent ovarian cancer.
OBJECTIVE:Maternal embryonic leucine-zipper kinase (MELK) shows oncogenic properties in basal-like breast cancer, a cancer subtype sharing common molecular features with high-grade serous ovarian cancer. We examined the potential of MELK as a molecular and pharmacological target for treatment of epithelial ovarian cancer (EOC). METHODS/MATERIALS: Bioinformatic analysis was performed on nine OC transcriptomic data sets totaling 1241 patients. Effects of MELK depletion by shRNA or inhibition by OTSSP167 in cell lines were assessed by colony formation and MTT (proliferation) assays, Western blotting (apoptosis), and flow cytometry (cell cycle analysis). RESULTS: Elevated MELK expression was correlated with histological grading (n=6 data sets, p<0.05) and progression-free survival (HR 5.73, p<0.01) in OC patients and elevated MELK expression in other cancers with disease-free survival (n=3495, HR 1.071, p<0.001). Inhibition or depletion of MELK reduced cell proliferation and anchorage-dependent and -independent growth in various OC cell lines through a G2/M cell cycle arrest, eventually resulting in apoptosis. OTSSP167 retained its cytotoxicity in Cisplatin- and Paclitaxel-resistant IGROV1 and TYK-nu OC cells and sensitized OVCAR8 cells to Carboplatin but not Paclitaxel. CONCLUSION:MELK inhibition by OTSSP167 may thus present a strategy to treat patients with aggressive, progressive, and recurrent ovarian cancer.
Authors: Lakshmi Reddy Bollu; Jonathan Shepherd; Dekuang Zhao; Yanxia Ma; William Tahaney; Corey Speers; Abhijit Mazumdar; Gordon B Mills; Powel H Brown Journal: NPJ Breast Cancer Date: 2020-01-03
Authors: Alexandre Chlenski; Chanyoung Park; Marija Dobratic; Helen R Salwen; Brian Budke; Jae-Hyun Park; Ryan Miller; Mark A Applebaum; Emma Wilkinson; Yusuke Nakamura; Philip P Connell; Susan L Cohn Journal: Mol Cancer Ther Date: 2019-01-23 Impact factor: 6.261
Authors: Abel Trujillo-Ocampo; Febe Elena Cázares-Raga; Rosa María Del Angel; Fernando Medina-Ramírez; Leopoldo Santos-Argumedo; Mario H Rodríguez; Fidel de la Cruz Hernández-Hernández Journal: Parasit Vectors Date: 2017-08-01 Impact factor: 3.876